Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

NCT05836584 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05836584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 6, 2023
Completion date
June 28, 2027
Enrollment
2 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i gastric cancer ajcc v8, clinical stage i gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ii gastric cancer ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma